SCHEMBL905990

SCHEMBL905990

CC(N)Cc1n[nH]c2ccc(Br)cc12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDPK1 O15530 3/20 0.54
JAK2 O60674 3/20 0.54
CLK4 Q9HAZ1 3/20 0.45
FLT3 P36888 2/20 0.45
DCLK1 O15075 2/20 0.45
PRKD3 O94806 2/20 0.45
MAP4K4 O95819 2/20 0.45
CDK2 P24941 2/20 0.45
MARK3 P27448 2/20 0.45
CLK2 P49760 2/20 0.45
CSNK2A1 P68400 2/20 0.45
CSNK1G2 P78368 2/20 0.45
CAMK2B Q13554 2/20 0.45
CAMK2G Q13555 2/20 0.45
DYRK1A Q13627 2/20 0.45
MELK Q14680 2/20 0.45
MARK2 Q7KZI7 2/20 0.45
HIPK4 Q8NE63 2/20 0.45
BRSK1 Q8TDC3 2/20 0.45
AURKB Q96GD4 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Fumaric Acid SCHEMBL8151973 0.89 NPSR1 (0.46) PDPK1JAK2CLK4FLT3DCLK1
SCHEMBL7486071 0.88 JAK2 (0.53) PDPK1JAK2CLK4FLT3DCLK1
SCHEMBL905771 0.82 HTR2A (0.55) JAK2CLK4DCLK1PRKD3MAP4K4
SCHEMBL5987890 0.82 HTR2A (0.55) PDPK1JAK2CLK4DCLK1PRKD3
Hydrochloric Acid SCHEMBL5989450 0.81 HTR1A (0.54) PDPK1JAK2CLK4DCLK1PRKD3
SCHEMBL906084 0.79 HTR2A (0.57) HTR2AHTR2CHTR2BHTR1A
SCHEMBL182234 0.79 PDPK1 (0.58) PDPK1JAK2CLK4FLT3DCLK1
SCHEMBL30166149 0.78 SLC6A2 (0.50) PDPK1HTR2AHTR2CHTR2BHTR1A
SCHEMBL5989957 0.78 SLC6A2 (0.50) PDPK1HTR2AHTR2CHTR2BHTR1A
SCHEMBL27577588 0.77 MAPK1 (0.46) PDPK1JAK2CLK4DCLK1PRKD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2000012482-A2 INDAZOLE DERIVATIVES WITH 5-HT2 RECEPTOR ACTIVITY VERNALIS RESEARCH LIMITED (GB) 2000-03-09 WO claimed
US-20110152272-A1 Treatment Of Incontinence PFIZER INC 2011-06-23 US disclosed
EP-2277513-A2 Treatment of incontinence with 5htc2 agonists Pfizer Inc. (US) 2011-01-26 EP disclosed
CN-1780612-B Treatment of incontinence with 5HT2C agonists. PFIZER 2010-12-01 CN disclosed
US-20080146583-A1 Treatment of Incontinence PFIZER INC 2008-06-19 US disclosed
CN-1780612-A Treatment of incontinence with 5HT2C agonists. PFIZER (US) 2006-05-31 CN disclosed
EP-1620081-A2 TREATMENT OF INCONTINENCE WITH 5HTC2 AGONISTS Pfizer Limited (GB) 2006-02-01 EP disclosed
US-20040235856-A1 Treatment of incontinence PFIZER INC 2004-11-25 US disclosed
WO-2004096196-A2 TREATMENT OF INCONTINENCE WITH 5HTC2 AGONISTS PFIZER LIMITED (GB) 2004-11-11 WO disclosed
WO-2000012482-A2 INDAZOLE DERIVATIVES WITH 5-HT2 RECEPTOR ACTIVITY VERNALIS RESEARCH LIMITED (GB) 2000-03-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040235856-A1 Treatment of incontinence HTR2C, HTR5A, ADRA2C PDPK1 4542/4885JAK2 3380/4885CLK4 1352/4885
US-20110152272-A1 Treatment Of Incontinence HTR2C, HTR5A, ADRA2C PDPK1 4542/4885JAK2 3380/4885CLK4 1352/4885
US-20080146583-A1 Treatment of Incontinence HTR2C, HTR5A, ADRA2C PDPK1 4542/4885JAK2 3380/4885CLK4 1352/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.